FLNA - CASSAVA SCIENCES INC

1.61
-0.050   -3.106%

Share volume: 327,923
Last Updated: 04-24-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.11%

PREVIOUS CLOSE
CHG
CHG%
$1.66
-0.05
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
21%
Profitability 25%
Dept financing 1%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-8.00%
1 Month
-12.02%
3 Months
-20.69%
6 Months
-57.63%
1 Year
2.55%
2 Year
-92.59%
Key data
Stock price
$1.61
P/E Ratio 
N/A
DAY RANGE
$1.60 - $1.67
EPS 
-$1.88
52 WEEK RANGE
$1.45 - $4.98
52 WEEK CHANGE
$1.26
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
48.308 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-09-2025
BETA 
1.64
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$429,233
AVERAGE 30 VOLUME 
$370,369
Company detail
CEO: Remi Barbier
Region: US
Website: cassavasciences.com
Employees: 30
IPO year: 2000
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial.

Recent news